Eli Lilly's Mounjaro has become the leading brand in India's rapidly growing GLP-1 market. A massive shift toward injectable diabetes and obesity medications is reshaping the pharmaceutical landscape.

  • Mounjaro (Tirzepatide) is now the highest-selling GLP-1 brand in India.
  • The GLP-1 market reached a valuation of ₹2,333 crore, with injectables making up 86% of sales.
  • Generic entries have expanded patient access by making high-cost treatments more affordable.

The landscape of diabetes and obesity management in India is undergoing a seismic shift. Mounjaro, the blockbuster drug from Eli Lilly, has ascended to the top of the GLP-1 medicine market. According to data from Pharmarack's PharmaTrac, the segment saw a staggering 74% growth in units in August alone, with the total market value for the year ending August reaching ₹2,333 crore.

The Dominance of Injectables

A critical trend emerging in the Indian market is the overwhelming preference for injectable formulations over oral medications. Injectables accounted for ₹2,010 crore, or approximately 86% of the total GLP-1 market in August 2026. This is a massive leap from the previous year, when injectables were valued at only ₹348 crore.

Read Also:Bowel Cancer Patients Avoid Major Surgery After Groundbreaking Trial
Drug Molecule Market Share Value (INR)
Tirzepatide 62% ₹1,456 Crore
Semaglutide 34% ₹782 Crore
Others 4% Various

Why This Matters

BozokMedia analysis shows that India is transitioning from traditional diabetes management to advanced metabolic therapies. The surge in GLP-1 adoption indicates a growing societal focus on obesity as a chronic disease rather than a lifestyle choice. However, the divergence between unit growth and value growth suggests a shift toward higher-dose regimens and premium pricing.

"Generics have just increased the size of the pie, bringing in patients who were eligible but previously unable to afford the treatment."

The Role of Generics and Market Stabilization

The entry of generic versions has played a pivotal role in democratizing access to these life-altering drugs. While the original brands have maintained their growth, the lower price points of generics have expanded the overall patient pool. However, industry experts warn that growth may now enter a stabilization phase as the immediate eligible patient base has been largely onboarded.

Mounjaro specifically recorded sales of ₹1,256 crore over the last 12 months, representing a massive 502% growth in sales value. This suggests that while the number of new patients might be leveling off, the value per patient is increasing due to dosage adjustments.

Broader Pharmaceutical Context

The GLP-1 boom is part of a larger trend in the Indian pharma sector. Other categories such as cardiac medicines (15% growth) and anti-cancer drugs (13.9% growth) also showed double-digit increases. The total Indian pharmaceutical market is now valued at ₹2,58,977 crore, with Sun Pharmaceutical Industries maintaining its lead as the largest player.

Did You Know?: GLP-1 agonists mimic a hormone that stimulates insulin secretion and slows gastric emptying, which is why they are so effective for both blood sugar control and weight loss.

Frequently Asked Questions

Q1: Are GLP-1 drugs only for weight loss?
A: No, they were primarily developed for Type-2 diabetes management, though their efficacy in weight reduction has led to widespread use for obesity.

Q2: Why are injectables preferred over tablets in the GLP-1 market?
A: Injectable versions like Tirzepatide and Semaglutide often offer higher potency and better clinical outcomes compared to their oral counterparts.